ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 8月 12, 2026
$4.45
· 52週範囲の%
· 安値より上
· 高値へ
$3.6752週安値
$5.4552週高値
時価総額 (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
収益 (TTM)
$182M
あなたのバッジ
52週レンジ
$4–$5
アナリスト評価
STRONG BUY
目標株価
$5
P/E
5.6
ROE
89.6%
純利益率
84.2%
バッジストリップは空です。このページ上の任意の指標をピン留めしてください。
ABUS 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$4.45
時価総額 (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
収益 (TTM)
$182M
ROE (TTM)
89.6%
52週レンジ
$4–$5
ABUS 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
範囲
バー
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
株式分割
| 権利落ち日 | 分割 | タイプ |
|---|---|---|
| 2010年11月4日 | 1-for-5 | 逆 |
Arbutus Biopharma Corporation - Common Stock について Wikipediaからの企業概要
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
セクターHealthcare
業種Biotechnology
従業員19
国CA
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益$14M2016-12-31 → 2025-12-31
EPS$-0.172016-12-31 → 2025-12-31
フリーキャッシュフロー$-40M2016-12-31 → 2025-12-31
純利益率84.2%2016-12-31 → 2025-12-31
バリュエーションと指標
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
| 指標 | 5年トレンド | ABUS | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | 5.65年平均 ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.85年平均 ≈50.1 | ≈50.1 | 10.3 | 割安 | |
| 株価純資産倍率 (MRQ) | 3.45年平均 ≈5.7 | ≈5.7 | 3.7 | 適正価格 | |
| Price / FCF (株価FCF倍率) | -22.15年平均 ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow (株価収益率（P/CF）) | -22.15年平均 ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book (株価純資産倍率（P/TB）) | 11.45年平均 ≈5.7 | ≈5.7 | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | ABUS | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | 82.0%5年平均 ≈-555.0% | ≈-555.0% | -588.2% | 同水準 | |
| EBITDA Margin (EBITDAマージン) | -271.0%5年平均 ≈-555.0% | ≈-555.0% | -588.2% | 同水準 | |
| 純利益率 (TTM) | 84.2%5年平均 ≈-528.9% | ≈-528.9% | -507.2% | 同水準 | |
| ROA (TTM) | 81.1%5年平均 ≈-40.5% | ≈-40.5% | -29.6% | 同水準 | |
| ROE (TTM) | 89.6%5年平均 ≈-55.0% | ≈-55.0% | -42.0% | 同水準 |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | ABUS | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 流動比率 (MRQ) | 81.45年平均 ≈9.7 | ≈9.7 | 9.6 | 高流動性 | |
| Quick Ratio (クイックレシオ) | 15.55年平均 ≈9.5 | ≈9.5 | 6.6 | 同水準 |
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | ABUS | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益（前年比）) | 128.2%5年平均 ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y (収益（3年CAGR）) | -28.8%5年平均 ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y (収益（5年CAGR）) | 15.3% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | ABUS | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 0.15年平均 ≈0.1 | ≈0.1 | 0.2 | 弱い | |
| Receivables Turnover (売掛金回転率) | 7.35年平均 ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee (年間売上高 ÷ 従業員数（yfinanceの報告ヘッドカウント）。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$741.2K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
581.5%
次回決算
11月 11, 2026
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 8月 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| 2026年3月31日 | 5月 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| 2025年12月31日 | $-0.02 | $-0.04 | 44.0% | |
| 2025年9月30日 | $-0.04 | $-0.03 | -26.6% | |
| 2025年6月30日 | $0.01 | $-0.05 | 120.6% | |
| 2025年3月31日 | $-0.13 | $-0.11 | -23.2% | |
| 2024年12月31日 | $-0.07 | $-0.08 | 14.2% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM）
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
バリュエーション（TTM）
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 収益 | $14M | $6M | $18M | $39M | $11M |
| 営業利益率 % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| 純利益 | $-34M | $-70M | $-73M | $-69M | $-76M |
| 希薄化後EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流動比率 | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| クイックレシオ | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-40M | $-65M | $-87M | $-36M | $-68M |
機関投資家（13F） 187 提出者 · $719.6M合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
保有者
187
保有価値
$719.6M
新規ポジション
35
解消済みポジション
23
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 35 (+3 前期比) | 23 (-8 前期比) | 62 (+13 前期比) | 42 (-10 前期比) | +466K |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| Two Seas Capital LP | $91,658,798 | 19,095,583 | 12.74% | 株式数 |
| MORGAN STANLEY | $84,951,868 | 17,698,305 | 11.81% | 株式数 |
| Whitefort Capital Management, LP | $75,812,453 | 15,794,261 | 10.54% | 株式数 |
| BlackRock, Inc. | $66,077,140 | 13,766,071 | 9.18% | 株式数 |
| VANGUARD GROUP INC | $44,456,122 | 9,242,437 | 6.18% | 株式数 |
| STATE STREET CORP | $37,772,059 | 7,869,179 | 5.25% | 株式数 |
| Rubric Capital Management LP | $36,158,098 | 7,532,937 | 5.03% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33,651,259 | 7,010,679 | 4.68% | 株式数 |
| BARCLAYS PLC | $20,197,987 | 4,207,914 | 2.81% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $19,769,043 | 4,117,691 | 2.75% | 株式数 |
| GOLDMAN SACHS GROUP INC | $16,832,650 | 3,506,802 | 2.34% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $12,701,745 | 2,646,197 | 1.77% | 株式数 |
| BlackBarn Capital Partners LP | $12,000,000 | 2,500,000 | 1.67% | 株式数 |
| Legal & General Group Plc | $11,837,409 | 2,466,127 | 1.65% | 株式数 |
| Woodline Partners LP | $10,952,909 | 2,281,856 | 1.52% | 株式数 |
| Jefferies Financial Group Inc. | $8,216,026 | 1,711,672 | 1.14% | 株式数 |
| NOMURA HOLDINGS INC | $7,857,989 | 1,637,081 | 1.09% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7,398,998 | 1,541,458 | 1.03% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,869,846 | 1,431,218 | 0.95% | 株式数 |
| NORTHERN TRUST CORP | $6,811,315 | 1,419,024 | 0.95% | 株式数 |
| OSAIC HOLDINGS, INC. | $6,469,756 | 1,347,866 | 0.90% | 株式数 |
| ADAR1 Capital Management, LLC | $6,087,106 | 1,268,147 | 0.85% | 株式数 |
| Deltroit Asset Management (UK) LLP | $5,760,000 | 1,200,000 | 0.80% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $5,449,738 | 1,135,362 | 0.76% | 株式数 |
| CITIGROUP INC | $4,220,338 | 879,237 | 0.59% | 株式数 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3,771,945 | 838,210 | 0.52% | 株式数 |
| BANK OF MONTREAL /CAN/ | $3,734,102 | 777,938 | 0.52% | 株式数 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3,123,360 | 650,700 | 0.43% | 株式数 |
| MACKENZIE FINANCIAL CORP | $2,946,269 | 613,806 | 0.41% | 株式数 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2,889,638 | 602,008 | 0.40% | 株式数 |
| Western Standard LLC | $2,605,378 | 542,787 | 0.36% | 株式数 |
| Rangeley Capital, LLC | $2,400,000 | 500,000 | 0.33% | 株式数 |
| Nuveen, LLC | $2,383,723 | 496,609 | 0.33% | 株式数 |
| Man Group plc | $2,272,642 | 473,467 | 0.32% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $2,215,900 | 461,646 | 0.31% | 株式数 |
| Bank of New York Mellon Corp | $2,179,752 | 454,115 | 0.30% | 株式数 |
| CenterBook Partners LP | $2,136,725 | 445,151 | 0.30% | 株式数 |
| Freestone Capital Holdings, LLC | $2,124,000 | 442,500 | 0.30% | 株式数 |
| CITADEL ADVISORS LLC | $1,942,541 | 404,696 | 0.27% | 株式数 |
| KENNEDY CAPITAL MANAGEMENT LLC | $1,849,430 | 385,298 | 0.26% | 株式数 |
| D. E. Shaw & Co., Inc. | $1,832,942 | 381,863 | 0.25% | 株式数 |
| Swiss National Bank | $1,375,200 | 286,500 | 0.19% | 株式数 |
| Ledgewood Wealth Advisors, LLC | $1,336,493 | 278,436 | 0.19% | 株式数 |
| FMR LLC | $1,282,503 | 267,188 | 0.18% | 株式数 |
| Susquehanna Portfolio Strategies, LLC | $1,265,688 | 263,685 | 0.18% | 株式数 |
| Carrera Capital Advisors | $1,234,402 | 257,167 | 0.17% | 株式数 |
| Quinn Opportunity Partners LLC | $1,225,027 | 255,214 | 0.17% | 株式数 |
| Invesco Ltd. | $1,204,353 | 250,907 | 0.17% | 株式数 |
| UBS Group AG | $1,196,198 | 249,208 | 0.17% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,161,682 | 242,017 | 0.16% | 株式数 |
アクティビストおよび5%超のオーナー 8保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 提出書類 | 2026年4月28日 | 8.00% | 修正 | · | SEC |
| Roivant Sciences Ltd. ×14 提出書類 | 2025年2月25日 | 20.50% | 修正 | · | SEC |
| Patrick Machado ×4 提出書類 | 2019年7月17日 | · | 初回提出 | · | SEC |
| Dr. Andrew Lo ×5 提出書類 | 2019年7月17日 | · | 初回提出 | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 提出書類 | 2019年7月12日 | · | 初回提出 | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 提出書類 | 2019年7月12日 | · | 初回提出 | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 提出書類 | 2019年7月12日 | · | 初回提出 | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 提出書類 | 2019年7月12日 | · | 初回提出 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 35 人のインサイダー · 17人の役員 · 19人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | 2026年9月18日 M | 72,337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | 2025年2月14日 A | 1,658,003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | 2023年2月1日 A | 216,500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 2019年3月1日 A | 341,396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | 2026年9月18日 M | 159,963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 2025年2月14日 A | 249,824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 2017年3月24日 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | 2025年2月14日 A | 155,494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | 2025年2月14日 A | 140,544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 2024年2月1日 A | 1,485,121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | 2023年2月1日 A | 86,024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 2022年1月20日 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 2018年12月11日 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 2018年4月16日 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 2017年3月24日 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 2016年8月16日 M | 42,097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 2016年3月15日 A | · | 0 | 0 | $0 |
| Roger Sawhney | 取締役 | 2026年9月18日 M | 30,825 | 0 | 0 | $0 |
| Robert A Beardsley | 取締役 | 2026年9月18日 M | 32,276 | 0 | 0 | $0 |
| Anuj Hasija | 取締役 | 2025年3月18日 A | · | 0 | 0 | $0 |
| Keith S Manchester | 取締役 | 2024年8月14日 M | 46,069 | 0 | 0 | $0 |
| Melissa Rewolinski | 取締役 | 2024年5月23日 A | · | 0 | 0 | $0 |
| Frank Torti | 取締役 | 2024年5月23日 A | · | 0 | 0 | $0 |
| James R Meyers | 取締役 | 2024年5月23日 A | · | 0 | 0 | $0 |
| Daniel D Burgess | 取締役 | 2024年5月23日 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | 取締役 | 2024年5月23日 A | 1,000 | 0 | 0 | $0 |
| Tram Tran | 取締役 | 2022年5月25日 A | · | 0 | 0 | $0 |
| Andrew Cheng | 取締役 | 2021年6月3日 A | · | 0 | 0 | $0 |
| Myrtle S Potter | 取締役 | 2019年8月17日 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | 取締役 | 2018年6月19日 A | · | 0 | 0 | $0 |
| Herbert J Conrad | 取締役 | 2018年6月19日 A | · | 0 | 0 | $0 |
| Frank Karbe | 取締役 | 2017年6月21日 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10%オーナー | 2021年10月18日 C | 38,847,462 | 0 | 0 | $0 |
| Andrew Lo | 10%オーナー | 2018年1月12日 P | · | 0 | 0 | $0 |
| Patrick Machado | 10%オーナー | 2018年1月12日 P | · | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
ETF保有状況 26のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.68% | 72,962 NS | 2026年7月31日 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.62% | 521,191 NS | 2026年7月31日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.47% | 23,611 SH | 2026年10月2日 | 日次 |
| IWC · iShares Trust | 0.19% | 545,721 SH | 2026年9月11日 | 日次 |
| LABU · Direxion Shares ETF Trust | 0.11% | 124,896 NS | 2026年7月31日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.06% | 14,124 SH | 2026年10月2日 | 日次 |
| IBB · iShares Trust | 0.06% | 1,201,130 SH | 2026年9月11日 | 日次 |
| IWO · iShares Trust | 0.05% | 1,506,889 SH | 2026年9月11日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.05% | 172,487 SH | 2026年8月19日 | 日次 |
| PWS · Pacer Funds Trust | 0.03% | 1,706 NS | 2026年7月31日 | N-PORT |
| IWM · iShares Trust | 0.03% | 4,035,105 SH | 2026年9月11日 | 日次 |
| RSSL · Global X Funds | 0.02% | 76,843 NS | 2026年7月31日 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 120,110 SH | 2026年10月2日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 925,044 SH | 2026年8月19日 | 日次 |
| ISCG · iShares Trust | 0.01% | 24,707 SH | 2026年9月11日 | 日次 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 1,810,587 SH | 2026年8月19日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.01% | 430,244 SH | 2026年8月19日 | 日次 |
| WSML · iShares Trust | 0.01% | 11,624 SH | 2026年9月9日 | 日次 |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 66,333 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 265,986 SH | 2026年9月11日 | 日次 |
| IWV · iShares Trust | 0.00% | 49,783 SH | 2026年9月9日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5,034,547 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 13,683 SH | 2026年8月19日 | 日次 |
| ISCB · iShares Trust | · | 6,673 SH | 2026年9月11日 | 日次 |
| ISCV · iShares Trust | · | 13,314 SH | 2026年9月11日 | 日次 |
| SMMV · iShares Trust | · | 60,845 SH | 2026年9月1日 | 日次 |
ABUS アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
レーティング · 7 アナリスト
買い
中央値ターゲット
$5.39
+21.0%
3 42.9%
強い買い
3 42.9%
買い
1 14.3%
保有
0 0.0%
売り
0 0.0%
強い売り
12ヶ月目標株価
1 アナリスト · 2026-09-28平均値ターゲット $5.39 +21.0%
安値$5.39
平均値$5.39
高値$5.39
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
出典：SEC 10-Q 提出日 8月 12, 2026